REGN Maintained by RBC Capital -- Price Target Raised to $810
RBC Capital maintained a 'Sector Perform' rating for Regeneron Pharmaceuticals (REGN) but raised its price target to $810 from $737. REGN is trading at $729.42, which is 20.2% undervalued according to its GF Value™ of $914.40. The company has a GF Score™ of 87/100, indicating strong financial health and growth prospects. 10 gurus hold REGN, with 8 increasing their positions recently.
How this was made
The 30-second read
Why it matters
The rating maintenance combined with a higher price target suggests a modest bullish catalyst for the stock.
Market read
Analyst target raise is a typical catalyst that can move the stock modestly in the short term.
What to watch
Potential competitive pressure on Eylea and Dupixent could limit upside.
Background
RBC Capital adjusted its outlook for Regeneron, reflecting confidence in its pipeline and recent guru buying.
Ticker impact
RBC Capital maintained its rating and raised REGN's price target to $810, a new analyst action.
likely upward pressure as investors price in the higher target
The price‑target lift signals stronger growth expectations and aligns with recent guru buying, prompting potential demand.
Market effects
Biotech sector may see modest uplift as a leading peer receives a higher target.
U.S. markets could see slight positive bias in healthcare indices.
Limited to investors tracking U.S. biotech stocks.
Counterpoint
The target raise may be premature if upcoming trial data disappoints.
Key entities
- CompanyRegeneron Pharmaceuticals
Biotech firm with products Eylea and Dupixent.
- AnalystRBC Capital
Investment bank providing the rating and target.
